Blog
RSS FeedPosted by Michael Wonder on 09 Jan 2019
PBAC - 2018 in review (cancer)
10 January 2019 - The PBAC considered many submissions for new cancer medicines (new medicine, new indication and new combination ...
Posted by Michael Wonder on 07 Jan 2019
PBAC - 2018 in review
7 January 2019 - The PBAC considered 195 submissions in 2018; 173 were considered by the PBAC in 2017. ...
Posted by Michael Wonder on 15 Dec 2018
Recommendations made by the PBAC - November 2018
14 December 2018 - The outcomes from the November 2018 PBAC meeting are now available but not in full. ...
Posted by Michael Wonder on 11 Nov 2018
Novartis' erenumab proving to be a headache for the PBAC
12 November 2018 - Record number of consumer comments; place in clinical therapy unclear. ...
Posted by Michael Wonder on 10 Nov 2018
Public Summary Documents - July 2018 PBAC meeting
9 November 2018 - The second tranche of Public Summary Documents from the July 2018 PBAC meeting (first time rejections and ...
Posted by Michael Wonder on 31 Oct 2018
More insights from the first tranche of Public Summary Documents from the July 2018 PBAC meeting
31 October 2018 - A thorough examination of the Public Summary Documents from the July 2018 PBAC meeting has identified ...
Posted by Michael Wonder on 28 Sep 2018
Recommendations made by the PBAC – August 2018
28 September 2018 - The recommendations from the August 2018 PBAC meeting are now available. ...
Posted by Michael Wonder on 28 Sep 2018
Publication of outcome from August 2018 PBAC special meeting
28 September 2018 - The brief outcome from the August 2018 special meeting regarding PD-1 and PD-L1 checkpoint inhibitor immunotherapies: options ...
Posted by Michael Wonder on 04 Sep 2018
Why aren't final base-case ICERs published in the PBAC Public Summary Documents?
5 September 2018 - The case for not doing so is now very weak. ...
Posted by Michael Wonder on 31 Aug 2018
Pharma interactions educate and improve health outcomes
31 August 2018 - Medicines Australia is pleased to announce the release of the fifth biannual innovative medicines industry’s transfer ...
Posted by Michael Wonder on 25 Aug 2018
Multiple myeloma meeting outcome statement
24 August 2018 - The outcome statement for the multiple myeloma stakeholder meeting held on 23 May 2018 is now available. ...
Posted by Michael Wonder on 19 Aug 2018
Insights from the July 2018 PBAC meeting
20 August 2018 - Highest recommendation rate for a scheduled PBAC meeting in modern times. ...
Posted by Michael Wonder on 18 Aug 2018
Life saving cancer drug Keytruda worth $150,000 goes on the PBS
19 August 2018 - Melbourne academic and lung cancer patient John Burke has spent $80,000 on the drug that saved ...
Posted by Michael Wonder on 18 Aug 2018
Pharmaceutical Benefits Advisory Committee recommends Orkambi for PBS
17 August 2018 - Cystic fibrosis sufferers across Australia will now have access to a life-changing drug after the Federal ...
Posted by Michael Wonder on 17 Aug 2018
Recommendations made by the PBAC - July 2018
17 August 2018 - The recommendations from the July 2018 PBAC meeting are now available. ...